Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date

RT @Lupusreference: The FDA decision about Saphnelo (#Anifrolumab) is still unknown and should be expected by August 2021. As a reminder, t…

RT @Lupusreference: The FDA decision about Saphnelo (#Anifrolumab) is still unknown and should be expected by August 2021. As a reminder, t…

The FDA decision about Saphnelo (#Anifrolumab) is still unknown and should be expected by August 2021. As a reminder, the TULIP-1 phase 3 trial did not meet its primary endpoint (SRI-4) while TULIP-2 did (BICLA). https://t.co/jht3eskRap

RT @Lupusreference: 🎯 What can we still expect from #anifrolumab in systemic #lupus? Are #interferon-targeting strategies still promising i…